Form 4 for BIIB Biogen
Accepted 2025-12-03 00:00:00 ET · period of report 2025-12-01 · accession 0000875045-25-000052 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-03 | 2025-12-01 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | M - OptEx | $0.00 | +7,040 | 19.8K | +55% | $0 |
| D | 2025-12-03 | 2025-12-01 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | F - Tax | $177.78 | -3,404 | 16.4K | -17% | -$605.2K |
| D | 2025-12-03 | 2025-12-01 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | M - OptEx | $0.00 | -7,040 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-01 | M | A | 7,040 | $0.00 | 19,847 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-01 | F | D | 3,404 | $177.78 | 16,443 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2025-12-01 | M | D | 7,040 | $0.00 | 0 | D | — · — to — | 7,040 Common Stock | (F1) Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of common stock. (F2) Each RSU vested on the third anniversary of the grant date of December 1, 2022. |